Register for OBR daily


COA_AnnualConf_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

BLRX $2.59 0.3500 +15.63%
ADXS $10.12 0.8000 +8.58%
ONCY $1.16 0.0900 +8.41%
OGXI $2.60 0.1900 +7.88%
CNDO $2.79 0.1900 +7.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CERU $7.58 -0.6600 -8.01%
MNKD $6.16 -0.4800 -7.23%
APRI $2.39 -0.1400 -5.53%
FGEN $30.35 -1.7400 -5.42%
FPRX $24.76 -1.3300 -5.10%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

D3 Oncology Solutions Launches Sabre™ Program for Accelerating SRS/SBRT Implementations

(D3 Oncology Solutions) July 26, 2011 – D3 Oncology Solutions today announced that it will begin offering a comprehensive product to radiation oncologists and surgeons to rapidly but safely implement a successful SRS/SBRT program.
read press release 



Scant Evidence to Link 9/11 to Cancer, U.S. Report Says

(New York Times) July 26, 2011 - A report from a federal agency said there was not enough evidence or research to say 9/11 had caused cancer.
read article 



New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility

(Reuters) July 27, 2011 - CancerTYPE ID is Now a Covered Benefit for Medicare Part B Patients.
read article 



Molecular Response Announces Key Agreement in Translational Oncology with SuperGen

(CNBC) July 27, 2011 - Molecular Response, a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an agreement with SuperGen, Inc.
read article 



ASCO Urges Policymakers to Protect Patient Access to Cancer Care from Debt Ceiling Negotiation Package

(ASCO in Action) July 27, 2011 - ASCO is deeply concerned about the proposed $3 billion in cuts to Medicare reimbursement as part of a debt ceiling negotiation package.
read article 



2011 Breast Cancer Symposium Co-Sponsors Announce Press Program

(ASCO) July 26, 2011 - Four noteworthy studies from the 2011 Breast Cancer Symposium will be featured in an embargoed presscast for reporters on Tuesday, September 6, 2011, from 12:00-1:30 PM (EDT). Highlighted studies will focus on improvements in the diagnosis, treatment and survival of breast cancer.
read press release 



Mammography Guidelines Gain ASBD Support

(Yahoo! Finance) July 26, 2011 - The American Society of Breast Disease (ASBD) strongly supports the new screening mammography guidelines of the American College of Obstetrics and Gynecology that recommends annual screening of all women ages 40 – 49.
read article 



More Evidence Needed to Show Benefits of Ambulight Photodynamic Therapy for Skin Cancer

(NICE) July 27, 2011 - NICE, the healthcare guidance body, has today (27 July) published its final guidance on the use of a device which delivers photodynamic therapy (PDT) to treat non-melanoma skin cancer in a way that allows patients to walk around freely whilst the treatment is given.
read press release 



Selective Internal Radiation Therapy for Non-Resectable Colorectal Metastases in the Liver

(NICE) July 27, 2011 - The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Selective internal radiation therapy for colorectal metastases in the liver in September 2004.
read article 



September 14, 2011: Oncologic Drugs Advisory Committee Meeting Announcement

(FDA) July 26, 2011 - During the morning session, the committee will discuss new drug application (NDA) 021825, with the proposed trade name FERRIPROX (deferiprone) film-coated tablets, application submitted by ApoPharma, Inc., represented by CATO Research Ltd. (authorized U.S. agent).
read article 



Keryx Biopharmaceuticals Announces Completion Of Patient Enrollment In KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study

(TheStreet) July 27, 2011 – Keryx Biopharmaceuticals, Inc. today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer.
read article 



Scientists Design Nano-Sized Drug Transporter to Fight Disease

(OSU) July 26, 2011 - Scientists seeking to improve cancer treatments have created a tiny drug transporter that maximizes its ability to silence damaging genes by finding the equivalent of an expressway into a target cell.
read press release 



Hormone Therapy May Be Hazardous for Men with Heart Conditions

(ASTRO) July 26, 2011 - Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer.
read press release 



Uncovering the Biology of Cancers in Adolescents and Young Adults

(NCI Cancer Bulletin) July 26, 2011 - Although the biology of AYA cancers is poorly understood, recent evidence suggests that some of these diseases may have unique genetic and biological features.
read article 



Vitamin D Relieves Joint, Muscle Pain for Breast Cancer Patients

(WUSM) July 26, 2011 - High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.
read press release 



Targeting PTEN May Prevent Skin Cancer

(AACR) July 26, 2011 - Scientists believe they have identified a role for PTEN, a known tumor suppressor, in removing DNA damage derived from UVB radiation, a known risk factor for non-melanoma skin cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
read press release 



Researchers Find 3 Genes Linked to Esophagus Disorders

(U.S. News & World Report) July 26 - Mutations in three genes have been found to be more common among people with disorders of the esophagus, including esophageal cancer and Barrett esophagus (a complication of gastroesophageal reflux disease), a new study shows.
read article 



New Breast Cancer Treatment for Women Resistant to Herceptin

(The Telegraph UK) July 27, 2011 - Lab tests suggest a newly developed protein may be effective in destroying HER2-positive tumours that have stopped responding to Herceptin.
read article 



UK Drug Body Backs Thalidomide, Velcade In Multiple Myeloma

(FOX Business/Dow Jones Newswires) July 26, 2011 - The U.K.'s health-care cost-effectiveness body Wednesday backed publicly funded use of Celgene Corp.'s thalidomide and Johnson & Johnson's bortezomib on the National Health Service for treating a type of bone marrow cancer called multiple myeloma.
read article 



Early-Stage Breast Cancer: Microscopic Tumor Spread is No Worry

(Los Angeles Times/Booster Shots blog) July 26, 2011 - Women with early-stage breast cancer have plenty of procedures and treatments to deal with. So it may come as welcome news that a large clinical trial has found no reason for doctors to perform two tests that were thought to help predict patient survival.
read article (free registration required) 



Biogen Idec Drug Gets European Approval

(Boston Globe) July 26, 2011 - Biogen Idec said it received conditional regulatory approval in Europe to market Fampyra, a treatment to improve walking in patients with multiple sclerosis.
read article (free registration required) 



Takeda Resubmits New Drug Applications to FDA

(Reuters) July 25, 2011 - Japan's largest drugmaker Takeda Pharmaceutical Co said it resubmitted two new drug applications (NDA) to the U.S. Food and Drug Administration (FDA) for investigational type 2 diabetes therapies.
read article 



Medco Gets US DOJ Subpoena Regarding 4 AstraZeneca Drugs

(Morningstar/Dow Jones Newswires) July 26, 2011 - The U.S. Department of Justice has issued subpoenas to drug-maker AstraZeneca PLC and pharmacy-benefit manager Medco Health Solutions Inc. seeking documents regarding their relationships involving four AstraZeneca drugs, including two that treat acid reflux and two for high blood pressure.
read article 



Lawsuit Says Drugs Were Wasted to Buoy Profit

(New York Times) July 25, 2011 - One of the nation’s largest providers of kidney dialysis deliberately wasted medicine in order to reap hundreds of millions of dollars in extra payments from Medicare, a former clinic nurse and a doctor are charging in a whistle-blower lawsuit.
read article 



Drug Prices to Plummet in Wave of Expiring Patents

(ABC News/AP) July 25, 2011 - The cost of prescription medicines used by millions of people every day is about to plummet…the magnitude of the wave of expiring drugs patents is unprecedented.
read article